Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated ...

Check the time stamp on this data. Updated AI-Generated Signals for Ionis Pharmaceuticals Inc. (IONS) available here: IONS.